160 related articles for article (PubMed ID: 34112534)
21. Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells.
Zhang J; Su L; Ye Q; Zhang S; Kung H; Jiang F; Jiang G; Miao J; Zhao B
Oncotarget; 2017 Jan; 8(5):7625-7636. PubMed ID: 28032588
[TBL] [Abstract][Full Text] [Related]
22. Apoptotic activities of brusatol in human non-small cell lung cancer cells: Involvement of ROS-mediated mitochondrial-dependent pathway and inhibition of Nrf2-mediated antioxidant response.
Xie J; Lai Z; Zheng X; Liao H; Xian Y; Li Q; Wu J; Ip S; Xie Y; Chen J; Su Z; Lin Z; Yang X
Toxicology; 2021 Mar; 451():152680. PubMed ID: 33465425
[TBL] [Abstract][Full Text] [Related]
23. Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis.
Qiu Y; Bai L; Zhao H; Mei X
BMC Cancer; 2024 Apr; 24(1):520. PubMed ID: 38658865
[TBL] [Abstract][Full Text] [Related]
24. Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4.
Hu T; Pan C; Zhang T; Ni M; Wang W; Zhang S; Chen Y; Wang J; Fang Q
Cancer Gene Ther; 2022 Nov; 29(11):1773-1790. PubMed ID: 35840666
[TBL] [Abstract][Full Text] [Related]
25. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
[TBL] [Abstract][Full Text] [Related]
26. Brusatol-Mediated Inhibition of c-Myc Increases HIF-1α Degradation and Causes Cell Death in Colorectal Cancer under Hypoxia.
Oh ET; Kim CW; Kim HG; Lee JS; Park HJ
Theranostics; 2017; 7(14):3415-3431. PubMed ID: 28912885
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
[TBL] [Abstract][Full Text] [Related]
29. n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activation.
Picou F; Debeissat C; Bourgeais J; Gallay N; Ferrié E; Foucault A; Ravalet N; Maciejewski A; Vallet N; Ducrocq E; Haddaoui L; Domenech J; Hérault O; Gyan E
Pharmacol Res; 2018 Oct; 136():45-55. PubMed ID: 30142422
[TBL] [Abstract][Full Text] [Related]
30. Brusatol hinders the progression of bladder cancer by Chac1/Nrf2/SLC7A11 pathway.
Yu X; He Z; Wang Z; Ke S; Wang H; Wang Q; Li S
Exp Cell Res; 2024 May; 438(2):114053. PubMed ID: 38663476
[TBL] [Abstract][Full Text] [Related]
31. Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.
Murakami Y; Sugiyama K; Ebinuma H; Nakamoto N; Ojiro K; Chu PS; Taniki N; Saito Y; Teratani T; Koda Y; Suzuki T; Saito K; Fukasawa M; Ikeda M; Kato N; Kanai T; Saito H
BMC Cancer; 2018 Jun; 18(1):680. PubMed ID: 29940898
[TBL] [Abstract][Full Text] [Related]
32. RNAi screening of the kinome with cytarabine in leukemias.
Tibes R; Bogenberger JM; Chaudhuri L; Hagelstrom RT; Chow D; Buechel ME; Gonzales IM; Demuth T; Slack J; Mesa RA; Braggio E; Yin HH; Arora S; Azorsa DO
Blood; 2012 Mar; 119(12):2863-72. PubMed ID: 22267604
[TBL] [Abstract][Full Text] [Related]
33. Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabine.
Shang Q; Pan C; Zhang X; Yang T; Hu T; Zheng L; Cao S; Feng C; Hu X; Chai X; Wang J; Fang Q
J Biol Chem; 2023 Jan; 299(1):102798. PubMed ID: 36528059
[TBL] [Abstract][Full Text] [Related]
34. Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.
Khoury H; He R; Schimmer A; Beadle JR; Hostetler KY; Minden MD
Chemotherapy; 2018; 63(4):225-237. PubMed ID: 30372692
[TBL] [Abstract][Full Text] [Related]
35. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
36. Modulators of the Nrf2 Signaling Pathway Enhance the Cytotoxic Effect of Standard Chemotherapeutic Drugs on Organoids of Metastatic Colorectal Cancer.
Razumovskaya AV; Silkina MO; Nikulin SV; Tonevitsky AG; Alekseev BY
Bull Exp Biol Med; 2024 Mar; 176(5):703-708. PubMed ID: 38724815
[TBL] [Abstract][Full Text] [Related]
37. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
38. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.
Ma J; Liu B; Yu D; Zuo Y; Cai R; Yang J; Cheng J
Br J Haematol; 2019 Oct; 187(1):49-64. PubMed ID: 31236919
[TBL] [Abstract][Full Text] [Related]
39. Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia.
Wang Y; Wang D; Wang Y; Yang H; Wang G; Wu S
Neoplasma; 2023 Apr; 70(2):287-293. PubMed ID: 36812234
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Ye R; Dai N; He Q; Guo P; Xiang Y; Zhang Q; Hong Z; Zhang Q
Biomed Pharmacother; 2018 Sep; 105():962-973. PubMed ID: 30021391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
